AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · IEX Real-Time Price · USD
7.20
+0.18 (2.56%)
Dec 29, 2023, 4:00 PM EST - Market closed
Company Description
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
AEON Biopharma, Inc. is based in Irvine, California.
AEON Biopharma, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Marc Forth |
Contact Details
Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States | |
| Phone | (949) 354-6499 |
| Website | aeonbiopharma.com |
Stock Details
| Ticker Symbol | AEON |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001837607 |
| CUSIP Number | 00775E102 |
| ISIN Number | US00791X1000 |
| Employer ID | 85-3940478 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 24, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Oct 23, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 19, 2023 | 8-K | Current Report |
| Oct 2, 2023 | 8-K | Current Report |
| Aug 22, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 22, 2023 | DEL AM | Filing |
| Aug 18, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 14, 2023 | 8-K/A | [Amend] Current report |